China Nepstar Chain Drugstore Ltd., Hangzhou 310003, Zhejiang, China.
Cardiovasc Toxicol. 2012 Dec;12(4):275-84. doi: 10.1007/s12012-012-9167-x.
Both clinical and experimental findings at the molecular, cellular, tissue, organ and systematic levels have depicted the presence of a contemporary regulatory machinery namely compensation in various forms of cardiovascular diseases. Compensation is believed to be present and regulated within the scope of a biological entity and represents the initiation of dyshomeostasis. Compensation can be identified in multiple categories and organs in cardiovascular diseases at multiple levels. The capacity to reduce the unfavorable pathological compensation may be a criterion to evaluate the therapeutic effectiveness for cardiovascular diseases. This mini-review tries to take compensation into consideration in the understanding of onset and progression of cardiovascular diseases in particular, and thus, better or optimal therapeutic approaches may be achieved for the prevention and management of cardiovascular diseases.
在分子、细胞、组织、器官和系统水平上的临床和实验发现都描绘了当代调节机制（即各种形式的心血管疾病中的代偿）的存在。代偿被认为存在于生物实体的范围内，并代表了失代偿的开始。代偿可以在多种类别的心血管疾病中在多个水平上被识别。减少不利的病理性代偿的能力可能是评估心血管疾病治疗效果的一个标准。这篇小型综述试图在理解心血管疾病的发生和进展时考虑到代偿，从而为心血管疾病的预防和治疗提供更好或更优化的治疗方法。
